Cover Image
市場調查報告書

全球微泡沫/超音波顯影劑市場預測:2015∼2021年

Global Microbubbles/Ultrasound Contrast Agents Market Outlook: 2015-2021

出版商 Meticulous Market Research Pvt.Ltd. 商品編碼 348582
出版日期 內容資訊 英文 176 Pages
訂單完成後即時交付
價格
Back to Top
全球微泡沫/超音波顯影劑市場預測:2015∼2021年 Global Microbubbles/Ultrasound Contrast Agents Market Outlook: 2015-2021
出版日期: 2015年09月19日 內容資訊: 英文 176 Pages
簡介

醫療影像用微泡沫/超音波顯影劑從研究階段發展到臨床階段。影像變鮮明,以及掃描的可靠性提高,有助於減少無用的檢驗。全球微泡沫/超音波顯影劑市場,預計從2015年到2020年以年複合成長率28.7%擴大,2020年達到7億9,750萬美元。

本報告提供全球微泡沫/超音波顯影劑市場相關調查、市場現狀與規模、市場佔有率、至2020年的預測、各產品/各地區的趨勢、競爭預測,及進入的主要企業簡介彙整。

第1章 微泡沫/超音波顯影劑市場簡介

第2章 摘要整理

第3章 市場概要

  • 商業上可取得的微泡沫
  • 商業上可取得的微泡沫顯影劑的全球普及度
  • 開發平台分析
  • 市場佔有率分析
  • 促進要素
  • 阻礙要素
  • 機會
  • 趨勢

第4章 各用途市場

  • 分子影像
    • 分子影像用微泡沫的清算
    • 優點
    • 應用領域
    • 趨勢
    • 課題
    • 機會
  • 基因治療
    • 簡介
    • 基因治療的方法
    • 研究的考察
    • 近幾年的研究
    • 產業的見解
  • 藥物遞輸
    • 簡介
    • 促進要素
    • 近幾年的研究
    • 產業的見解
  • 幹細胞遞送
    • 簡介
    • 近幾年的研究

第5章 各疾病的未來預測

  • 腎功能障礙
  • 心血管
  • 神經
  • 其他

第6章 近幾年的研究

第7章 各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 企業簡介

  • Lantheus Medical Imaging, Inc.
  • Bracco SpA
  • GE Healthcare
  • 第一三共株式會社

圖表

目錄
Product Code: BT 1051

Microbubbles are composed of gas core stabilized by a shell of proteins, lipids, or polymers and have unique ability to respond to ultrasound, and thus are used as ultrasound contrast agents. The field of ultrasound contrast imaging has been literally bursting in the last decade. Incessant engineering advances in ultrasound technologies over the last decade have resulted in widespread usage of ultrasound for clinical applications. The potential benefits of ultrasound such as low-cost, convenience, and real-time capability of ultrasound images has led to wide acceptance of this technology. When compared with other imaging modalities, the ultrasound molecular imaging has many advantages such as good temporal resolution, quantitative data, real-time practice, noninvasiveness, relatively inexpensive cost, and no ionizing radiation.

Microbubbles/ ultrasound contrast agents for medical imaging have been swiftly translated from exploratory research to clinical application. It helps to sharpen the image, improve the reliability of the scan and reduce the need for unnecessary downstream testing. In addition, microbubbles can be employed for diagnostic imaging and as a therapeutic tool. These are safe, convenient, completely radiation-free, versatile, and routinely used by physicians throughout the world to obtain a reliable ultrasound diagnosis.

The global microbubbles/ ultrasound contrast agents market is expected to grow at a CAGR of 28.7% to reach $797.5 million by 2021 from 2015. The research report on microbubbles market provides comprehensive analysis of the global market and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major applications such as molecular imaging, gene therapy, drug delivery, and stem cell delivery with their application areas, trends, challenges, and opportunities in this market. In addition, the report analyzes the global microbubbles market by various disease areas such as renal disorder, cardiovascular, and neurology with their drivers, restraints, ongoing research, and future potential.

The market has been segmented by geography as North America, Europe, Asia-Pacific, and Rest of the World (RoW) with a detailed qualitative and quantitative analysis. North America is the major market in the global microbubble market and is expected to dominate this market during the forecast period followed by Europe, and Asia-Pacific.

Lantheus Medical Imaging with its DEFINITY ultrasound contrast imaging agent dominated the global microbubbles/ ultrasound contrast agents market in 2014. The other major players in the global microbubble market include Bracco Imaging S. p. A., Daiichi Sankyo Company, Limited, and GE Healthcare.

Source: Expert Interviews, Government Authorities, Related associations/Institutes, Related Research Publications, Government Publications, Company Press Releases, Company Annual Reports, Company Websites, Company Publications, SEC Filings, Meticulous Research Analysis.

Table of Contents

1. Introduction to Global Microbubbles/Ultrasound Contrast Agents Market

  • 1.1. Microbubbles/Ultrasound Contrast Agents Market Ecosystem
  • 1.2. Report Elucidation
  • 1.3. Market Buzz and Foreground
  • 1.4. Types of microbubble shells
  • 1.5. Effects on microbubbles under ultrasound
  • 1.6. Research Methodology
    • 1.6.1. Secondary Research
    • 1.6.2. Primary Research
    • 1.6.3. Market Analytics

2. Executive Summary

3. Market Insights

  • 3.1. Commercially Available Microbubbles
  • 3.2. Global Penetration of Commercially Available Microbubble Contrast Agents
  • 3.3. Pipeline Analysis
  • 3.4. Market Share Analysis
  • 3.5. Drivers
    • 3.5.1. Technological Advancements to increase the adoption of microbubble contrast agents
      • 3.5.1.1. Evolution of Microbubbles
      • 3.5.1.2. Miniaturization of Ultrasound Devices
        • 3.5.1.2.1. Wearable Ultrasound Pain Therapy Device
        • 3.5.1.2.2. Flow Focusing Microfluidic Devices (FFMDs)
        • 3.5.1.2.3. Handheld Ultrasound Scanners
        • 3.5.1.2.4. Phone-based Ultrasound Systems
        • 3.5.1.2.5. New Generation Ultrasound Transducers
    • 3.5.2. Advantages of microbubble contrast agents over other technologies
    • 3.5.3. Favorable reimbursement policies for contrast-enhanced procedures to drive the market
    • 3.5.4. Rising demand for diagnostics and image-guided procedures influences the sales of microbubbles
  • 3.6. Restraints
    • 3.6.1. Complexity involved in conducting CEUS procedures to limit the market growth
    • 3.6.2. Limited training and financial resources restraints the market growth
  • 3.7. Opportunities
    • 3.7.1. Increase in researches related to microbubbles
    • 3.7.2. Rise in off-label usage of microbubble contrast agents
  • 3.8. Trends
    • 3.8.1. Journey through black-box warning
    • 3.8.2. Expansion – a key growth strategy followed by market players

4. Microbubbles/Ultrasound Contrast Agents Market, Future Prospects, By Application

  • 4.1. Molecular Imaging
    • 4.1.1. Production of Microbubbles for molecular imaging
      • 4.1.1.1. Passive Targeting
      • 4.1.1.2. Active Targeting
      • 4.1.1.3. Ligand Attachment to performed microbubbles
    • 4.1.2. Advantages of use of microbubbles in molecular imaging
    • 4.1.3. Application Areas
      • 4.1.3.1. Angiogenesis
      • 4.1.3.2. Angiosarcoma
      • 4.1.3.3. Oncology
    • 4.1.4. Trends In Molecular Imaging
      • 4.1.4.1. Development of Novel Microbubbles to Improve the Target Binding
      • 4.1.4.2. Development of Novel Microbubbles to Suit the Modalities Used in Imaging
        • 4.1.4.2.1. Photo Acoustic Imaging (PAI)
        • 4.1.4.2.2. Magnetic Resonance Imaging (MRI)
    • 4.1.5. Challenges
    • 4.1.6. Opportunities
      • 4.1.6.1. Researches to Improve Understanding of Microbubble Behavior
      • 4.1.6.2. Active Targeting
  • 4.2. Gene Therapy
    • 4.2.1. Introduction
    • 4.2.2. Methods of Gene Therapy
      • 4.2.2.1. Membrane Sonoporation
      • 4.2.2.2. Bi-layer Sonoporation
      • 4.2.2.3. Modulation of Vascular Integrity
      • 4.2.2.4. Stimulating Endocytotic Uptake
      • 4.2.2.5. Active Deliver of DNA Vectors Beyond the Vasculator
      • 4.2.2.6. Loading of Drug on Microbubble Surface
    • 4.2.3. Study Considerations
      • 4.2.3.1. Microbubble Surface Architecture
      • 4.2.3.2. Microbubble Size
      • 4.2.3.3. Molecular Targeting
      • 4.2.3.4. Ultrasound Parameters
    • 4.2.4. Recent Researches
    • 4.2.5. Industry Speaks
  • 4.3. Drug Delivery
    • 4.3.1. Introduction
    • 4.3.2. Drivers
      • 4.3.2.1. Growing Number of Researchers In The Field of Drug Delivery Using Microbubbles
      • 4.3.2.2. Rising Incidence & Mortality Of Cancer & Cardiac Disease To Create Need For Better Drug Therapies
      • 4.3.2.3. Growing Researches Involving Targeted Drug Delivery Using Microbubbles
    • 4.3.3. Recent Researches
    • 4.3.4. Industry Speaks
  • 4.4. Stem Cells Delivery
    • 4.4.1. Introduction
    • 4.4.2. Recent Researches

5. Microbubbles/Ultrasound Contrast Agents Market, Future Prospects, By Disease Area

  • 5.1. Renal Compramized Functions
    • 5.1.1. Ultrasound applications in kidney
      • 5.1.1.1. Diagnosis between Solid Renal Masses and Pseudo-tumors
      • 5.1.1.2. Differentiation between Cystic and Solid Lesions of the Kidneys
      • 5.1.1.3. Characterization of Complex Cystic Renal Masses
      • 5.1.1.4. Renal Infections
      • 5.1.1.5. Renal Trauma
      • 5.1.1.6. Renal Artery Stenosis
      • 5.1.1.7. Assessment of Percutaneous Ablation Therapy
      • 5.1.1.8. Kidney Fibrosis
      • 5.1.1.9. Kidney Transplantation
    • 5.1.2. Future Potential
      • 5.1.2.1. Imaging
      • 5.1.2.2. Drug Delivery
      • 5.1.2.3. Recent Researches
    • 5.1.3. Study Considerations
      • 5.1.3.1. Circulation Period
      • 5.1.3.2. Microbubbles Concentration
      • 5.1.3.3. Ultrasound Energy
      • 5.1.3.4. Size of the objest
    • 5.1.4. Drivers
      • 5.1.4.1. Regulatory Changes to Boost Clinical Research Related to Kidney
      • 5.1.4.2. Feasible Solution for Identification of Malignant Renal Vein Invasion
    • 5.1.5. Restraints
      • 5.1.5.1. Retention of Microbubbles
    • 5.1.6. Industry Speaks
  • 5.2. Cardiovascular
    • 5.2.1. Introduction
    • 5.2.2. Sonothrombolysis
      • 5.2.2.1. Introduction
      • 5.2.2.2. Mechanism
      • 5.2.2.3. Drivers
        • 5.2.2.3.1. High Incidence of Stroke
        • 5.2.2.3.2. Improvisation in therapies to boost the application in Sonothrombolysis
      • 5.2.2.4. Future Potential
    • 5.2.3. Targeted Microbubbles
      • 5.2.3.1. Introduction
      • 5.2.3.2. Structure of Targeted Microbubbles
      • 5.2.3.3. Recent Researches
        • 5.2.3.3.1. VEG-fR2 receptor (BR-55)
        • 5.2.3.3.2. Clot-targeted Microbubbles
        • 5.2.3.3.3. Endothelial Epitopes as Targets
        • 5.2.3.3.4. WBCs as Carriers of Microbubbles
      • 5.2.3.4. Accessible Targets for Targeted Microbubbles
      • 5.2.3.5. Future Potential
    • 5.2.4. Gene Therapy
      • 5.2.4.1. Ultrasound Target Microbubble Destruction (UTMD) in Cardiovascular
      • 5.2.4.2. Gene Delivery to Treat Diabetes
      • 5.2.4.3. Future Potential
    • 5.2.5. Recent Researches
    • 5.2.6. Industry Speaks
  • 5.3. Neurology
    • 5.3.1. Introduction
    • 5.3.2. The Blood Brain Barrier (BBB)
    • 5.3.3. Study Considerations
      • 5.3.3.1. Non-linear Behavior of Microbubbles
      • 5.3.3.2. Assessing the Nature of Target Drug
      • 5.3.3.3. Safety Assessment
    • 5.3.4. Drivers
      • 5.3.4.1. Limitations of Alternative Strategies for Drug Delivery Across BBB
      • 5.3.4.2. Advantages Offered by Microbubble in Drug Delivery in Brain
    • 5.3.5. Opportunities
      • 5.3.5.1. Development of Novel Microbubbles
      • 5.3.5.2. Increasing Researches Focused on Opening of BBB
    • 5.3.6. Recent Researches
    • 5.3.7. Industry Speaks
  • 5.4. Other Diseases
    • 5.4.1. Crohn’s Disease
      • 5.4.1.1. Introduction
      • 5.4.1.2. Recent Researches
    • 5.4.2. Atherosclerosis
      • 5.4.2.1. Introduction
      • 5.4.2.2. Recent Researches

6. Recent Researches on Microbubbles/Ultrasound Contrast Agents

7. Microbubbles/Ultrasound Contrast Agents Market, By Geography

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia-Pacific
  • 7.4. Rest of the World

8. Company Profiles

  • 8.1. Lantheus Medical Imaging, Inc.
  • 8.2. Bracco SpA
  • 8.3. GE Healthcare
  • 8.4. Daiichi Sankyo Company, Limited
Back to Top